Major Events - Longi Technology (09611) plans to globally offer 52.2591 million H-shares from January 14 to January 19 [1] - CK Life Sciences (00013) announced the results of the SACHI III study published in The Lancet [1] - Dongyang Sunshine Pharmaceutical (06887) launched an AI-driven R&D platform targeting the PROTAC mechanism, continuing to deepen its AI strategic layout [1] - Dongyao Pharmaceutical-B (01875) received a cash offer from WuXi AppTec (02268) at a premium of approximately 99%, with resumption of trading on January 15 [1] - Valiant Pharmaceuticals-B (09887) received Fast Track designation from the US FDA for its bispecific antibody, Opalizumab (LBL-024) [1] - Xunqi (03317) entered into a strategic cooperation framework agreement with Jinyong Investment to support digital transformation in investment research, trading, and risk management [1] Operating Performance - CITIC Securities (06030) reported a net profit attributable to shareholders of 30.051 billion yuan for 2025, an increase of 38.46% year-on-year [1] - CITIC Bank (00998) reported a net profit attributable to shareholders of 70.618 billion yuan for 2025, a year-on-year increase of 2.98% [1] - China General Nuclear Power New Energy (01811) completed a cumulative power generation of 19,000 GWh in 2025, a decrease of 0.8% year-on-year [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 106.21 billion yuan for 2025 [1] - WuXi AppTec (02268) issued a profit warning, expecting a net profit growth of over 38% year-on-year for 2025 [1] - Jinyu Group (02009) issued a profit warning, anticipating a net loss attributable to shareholders of 900 million to 1.2 billion yuan for 2025 [1] - Saijing Technology (00580) issued a profit alert, expecting a net profit increase of approximately 30.0% for 2025 [1] - Beijing Beichen Industrial Co., Ltd. (00588) issued a profit warning, expecting a net loss attributable to shareholders of 2.696 billion to 3.38 billion yuan for 2025 [1]

Core Viewpoint - Dongyangguang Pharmaceutical is advancing its AI strategy by launching an AI-driven research and development platform focused on the PROTAC mechanism, aiming to provide a comprehensive data foundation for rational design and clinical translation of PROTAC lead compounds [1][2]. Group 1: AI Strategy and Platform Development - The company is building a high-quality, structured PROTAC-specific database (HEC PROTAC DB) that integrates molecular structures, degradation activity, physicochemical properties, and pharmacokinetic parameters from clinical pipelines, patents, and literature [2]. - The database currently includes over 30,000 PROTAC molecules, more than 500 POI ligands, over 1,000 types of linkers, 200 E3 ligands, and more than 150 targets, significantly surpassing existing public databases in data scale and structural granularity [2]. - An AI molecular generation and screening platform has been developed based on this database, creating a "data-generation-computational validation-experimental feedback" closed loop to accelerate the rational design and clinical translation of PROTAC lead compounds [2]. Group 2: Collaboration and Drug Development - The company is enhancing its AI drug development strategy through collaborations with industry leaders such as Beijing Deep Technology Co., Ltd. and Huawei Cloud Computing Technology Co., Ltd., establishing six proprietary models covering the entire drug discovery process [3]. - The first AI-driven small molecule drug, HEC169584, targeting metabolic-associated fatty liver disease (MASH), has entered clinical phase I, showing high in vitro activity against THR-β cells and strong liver targeting, with reduced impact on the thyroid axis and heart [3].